Literature DB >> 15544634

Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement.

E Scala1, S Pallotta, A Frezzolini, D Abeni, C Barbieri, F Sampogna, O De Pità, P Puddu, R Paganelli, G Russo.   

Abstract

Systemic sclerosis (SSc) is a connective tissue disorder characterized by excessive collagen deposition in the skin and internal organs. Several cytokines and chemokines have been implicated in the induction of fibrosis, but a definitive relationship between specific cytokines and organ involvement has not been established yet. Serum samples, PBMC and T cell lines (TCL) obtained from 54 patients affected by SSc and 20 healthy donors (HD) were examined by ELISA for Interferon-gamma (IFN-gamma ), interleukin (IL)-4, IL-6, IL-10, IL-18, Transforming growth factor (TGF)-beta1, Tumour necrosis factor (TNF)-alpha, sCD30, Macrophage derived chemokine (MDC), Monocyte chemoattractant protein (MCP)-1, Macrophage inflammatory protein (MIP)-1alpha and Regulated on activation normal T-cell expressed and secreted (RANTES). In all the SSc serum samples, we found significantly increased levels of IL6, TNFalpha and MCP-1 but reduced amounts of gamma-IFN and MDC. IL6, IL10, IL18, MIP-1alpha and TNFalpha measured in supernatants from PHA-stimulated PBMC and IL6, MCP-1 and RANTES in supernatants from stimulated TCL were also increased in patients. MDC was decreased in all the biological SSc sources studied. TGF-beta1, IL10, and sCD30 were produced at a significantly lower level by SSc TCL. Serum IL6 and sCD30 levels were significantly increased in dc-SSc patients compared to lc-SSc as were levels of MCP-1 produced by PBMC and IL10 from TCL. We observed a strict relationship between pulmonary fibrosis and IL10, MCP-1 (both from TCL) and serum IL6. Kidney involvement was related to serum MCP-1 levels and IL18 production from PBMC. Oesophageal involvement correlated with MDC production from PBMC and IL10 synthesis by TCL. We showed that IL-6, IL-10, MDC and MCP-1 are variably associated with internal organ involvement and allow the discrimination between limited and diffuse forms of the disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15544634      PMCID: PMC1809238          DOI: 10.1111/j.1365-2249.2004.02642.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  61 in total

Review 1.  Peripheral blood fibrocytes: mesenchymal precursor cells and the pathogenesis of fibrosis.

Authors:  J Chesney; R Bucala
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

Review 2.  Assessment of damage and activity in systemic sclerosis.

Authors:  T A Medsger
Journal:  Curr Opin Rheumatol       Date:  2000-11       Impact factor: 5.006

Review 3.  Regulation of matrix biosynthesis and degradation in systemic sclerosis.

Authors:  R L Widom
Journal:  Curr Opin Rheumatol       Date:  2000-11       Impact factor: 5.006

4.  Expression of RANTES in biopsies of skin and upper gastrointestinal tract from patients with systemic sclerosis.

Authors:  O Distler; B Rinkes; U Hohenleutner; J Schölmerich; M Landthaler; B Lang; S Gay; U Müller-Ladner
Journal:  Rheumatol Int       Date:  1999       Impact factor: 2.631

5.  The interleukin-1, interleukin-2, interleukin-6 and tumour necrosis factor alpha serological levels in localised and systemic sclerosis.

Authors:  M Alecu; L Geleriu; G Coman; L Gălăţescu
Journal:  Rom J Intern Med       Date:  1998 Jul-Dec

6.  Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine.

Authors:  T Imai; M Nagira; S Takagi; M Kakizaki; M Nishimura; J Wang; P W Gray; K Matsushima; O Yoshie
Journal:  Int Immunol       Date:  1999-01       Impact factor: 4.823

7.  Immunological analysis of pulmonary hypertension in connective tissue diseases.

Authors:  T Nishimaki; S Aotsuka; H Kondo; K Yamamoto; Y Takasaki; M Sumiya; R Yokohari
Journal:  J Rheumatol       Date:  1999-11       Impact factor: 4.666

8.  Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis.

Authors:  S Sato; H Hanakawa; M Hasegawa; T Nagaoka; Y Hamaguchi; C Nishijima; K Komatsu; A Hirata; K Takehara
Journal:  J Rheumatol       Date:  2000-12       Impact factor: 4.666

9.  Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE).

Authors:  A Csiszár; G Nagy; P Gergely; T Pozsonyi; E Pócsik
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

10.  Macrophage-derived chemokine production by activated human T cells in vitro and in vivo: preferential association with the production of type 2 cytokines.

Authors:  G Galli; D Chantry; F Annunziato; P Romagnani; L Cosmi; E Lazzeri; R Manetti; E Maggi; P W Gray; S Romagnani
Journal:  Eur J Immunol       Date:  2000-01       Impact factor: 5.532

View more
  74 in total

1.  Serum concentrations of cyclooxygenase-2 in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis.

Authors:  Iman H Bassyouni; Roba M Talaat; Tarek A Salem
Journal:  J Clin Immunol       Date:  2011-10-07       Impact factor: 8.317

Review 2.  Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence?

Authors:  Giuseppina Stifano; Romy Beatriz Christmann
Journal:  Curr Rheumatol Rep       Date:  2016-01       Impact factor: 4.592

3.  CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease.

Authors:  Kylie A Alexander; Ryan Flynn; Katie E Lineburg; Rachel D Kuns; Bianca E Teal; Stuart D Olver; Mary Lor; Neil C Raffelt; Motoko Koyama; Lucie Leveque; Laetitia Le Texier; Michelle Melino; Kate A Markey; Antiopi Varelias; Christian Engwerda; Jonathan S Serody; Baptiste Janela; Florent Ginhoux; Andrew D Clouston; Bruce R Blazar; Geoffrey R Hill; Kelli P A MacDonald
Journal:  J Clin Invest       Date:  2014-08-26       Impact factor: 14.808

4.  Association between 'interleukin' 10 gene (IL10) polymorphisms and systemic sclerosis with interstitial lung involvement.

Authors:  O Ates; B Müsellim; G Ongen; A Topal-Sarikaya
Journal:  Rheumatol Int       Date:  2008-05-21       Impact factor: 2.631

5.  Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design.

Authors:  Dinesh Khanna; James R Seibold; Athol Wells; Oliver Distler; Yannick Allanore; Chris Denton; Daniel E Furst
Journal:  Curr Rheumatol Rev       Date:  2010-05-01

Review 6.  Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.

Authors:  Karen Au; Dinesh Khanna; Philip J Clements; Daniel E Furst; Donald P Tashkin
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

7.  B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.

Authors:  Silvia Bosello; Maria De Santis; Gina Lama; Cristina Spanò; Cristiana Angelucci; Barbara Tolusso; Gigliola Sica; Gianfranco Ferraccioli
Journal:  Arthritis Res Ther       Date:  2010-03-25       Impact factor: 5.156

8.  Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis.

Authors:  Nobuyo Higashi-Kuwata; Masatoshi Jinnin; Takamitsu Makino; Satoshi Fukushima; Yuji Inoue; Faith C Muchemwa; Yuji Yonemura; Yoshihiro Komohara; Motohiro Takeya; Hiroaki Mitsuya; Hironobu Ihn
Journal:  Arthritis Res Ther       Date:  2010-07-05       Impact factor: 5.156

9.  Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals.

Authors:  Christina M Martin; Jeffrey A Welge; Norah J Shire; Mohamed T Shata; Kenneth E Sherman; Jason T Blackard
Journal:  Cytokine       Date:  2009-07-21       Impact factor: 3.861

10.  Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients.

Authors:  Katrin Schmidt; Lorena Martinez-Gamboa; Susan Meier; Christian Witt; Christian Meisel; Leif G Hanitsch; Mike O Becker; Doerte Huscher; Gerd R Burmester; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2009-07-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.